Combining inhibitors of the BMP signaling pathway with standard chemotherapy drugs may overcome drug resistance in ovarian cancer.
Dineo Khabele, M.D., associate professor of Obstetrics and Gynecology and Cancer Biology, has been named to the Scientific Advisory Committee of the Ovarian Cancer Research Fund (OCRF).
Drugs that target DNA damage improve ovarian cancer cell response to platinum chemotherapies, suggesting new therapeutic opportunities.
The Kay Yow Cancer Fund, in partnership with the Women’s Basketball Coaches Association and The V Foundation for Cancer Research, has awarded a $100,000 ovarian cancer research grant to the Vanderbilt-Ingram Cancer Center.
The nuclear receptor TR3 contributes to ovarian cancer cell death in response to platinum-based chemotherapy – and may be a good target for overcoming cell resistance to certain treatments.
Cancer death rates for most forms of cancer have continued to decline in the United States among men and women and all major racial and ethnic groups, according to the latest Annual Report to the Nation on the Status of Cancer.